UCLB

What UCLB does

UCL Business Ltd (UCLB) is the wholly owned technology transfer and commercialisation subsidiary of University College London, established to monetise UCL's research output through two primary mechanisms. First, it operates the XIP electronic licensing portal at xip.uclb.com, which hosts an online catalogue of UCL-developed intellectual property — spanning software (bioinformatics, materials modelling, AI tools, clinical data modelling), biological materials (cell lines, vectors, GMOs), healthcare tools (37 clinical outcome assessments), hardware (Engduino), media, and publications — and supports both academic and commercial licensing via automated approval workflows and tiered pricing. Second, UCLB creates, incubates, and holds equity in spinout companies formed from UCL research, currently overseeing 95 active spinouts that span life sciences, deep tech (including silicon quantum computing via Quantum Motion), and AI; these spinouts have collectively raised £3.06bn in external capital over the past five years and employ over 2,300 people.

UCLB's go-to-market is hybrid: a sales-led motion in which dedicated business managers are assigned per UCL department to guide researchers through commercialisation, complemented by a channel-led motion connecting UCL IP to global academic and commercial licensees via XIP (reaching 191+ countries). Revenue is generated through IP licensing royalties and spinout equity stakes. Its customer base is segmented across UCL researchers and academics (primary), other academic and research institutions licensing materials and software, and commercial companies in biotech, healthcare, software, and manufacturing. Operationally, UCLB is preparing a corporate identity refresh and new website launch scheduled for 29 June 2026.

Management depth is anchored by Director of BioPharm Richard Fagan, Investment Director Simon Goldman, Director David Dutton, and Associate Director (Physical Sciences & Engineering) Marina Santilli. UCLB holds Cyber Essentials certification, is a Living Wage Employer, and was awarded 'Best Performing New Company Creator' in 2025. It participates in broader UCL initiatives, most notably the €60M LIGAND-AI consortium for AI-driven drug discovery with 18 partners across nine countries.

Name

UCLB

Legal name

UCL Business Ltd

Website

https://uclb.com

Company type

Private

Founded year

1993

Operating status

Operating

Headcount range

51–100 employees

Short description

UCLB is the wholly owned technology transfer and commercialisation company of University College London, monetising UCL research through IP licensing via its XIP portal and managing a portfolio of 95 active spinout companies.

Ownership category

akta.pro rank

Product category

Technology Transfer Services

NAICS

Colleges, Universities, and Professional Schools (611310), Scientific Research and Development Services (5417)

SIC

Patent Owners & Lessors (6794)

akta.pro primary industry

Research Administration & Compliance (Sponsored Programs, IRB/REB) (EDADAKAH)

Keywords

• Technology transfer services
• IP licensing platform
• University spinouts
• Research commercialization
• Academic technology transfer

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. IP Licensing: UCLB generates revenue through licensing intellectual property developed at UCL to commercial entities. This includes software licenses, biological materials (cell lines, GMOs, vectors), healthcare tools, and other technologies available through the XIP portal. Licenses are offered for both academic (non-commercial research) and commercial purposes.
2. Spinout Equity: UCLB creates and manages spinout companies from UCL research, holding equity stakes in portfolio companies that have collectively raised £3.06bn in external investment over five years.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

UCLB commercializes research from University College London academics by licensing intellectual property (software, biological materials, healthcare tools, hardware, publications) through its XIP online portal and by creating and managing spinout companies. It generates revenue via IP licensing fees/royalties, spinout equity, and commercialization support services for UCL researchers across life sciences, deep tech, and AI sectors.

Product overview

UCLB operates as UCL Business Ltd, a wholly owned subsidiary of University College London, functioning as the technology transfer office that commercializes UCL research. The primary product is XIP, an IP licensing portal that enables online browsing and licensing of intellectual property including biological materials (GMOs, cell lines, vectors), healthcare tools (clinical outcome assessments), software (bioinformatics, AI tools, materials modelling), hardware, and publications. The platform supports academic and commercial licensing with automated approval workflows. Beyond XIP, UCLB provides spinout company support, funding access, and commercialization services for UCL researchers.

Differentiator

Problem solved

Functional benefit

Brands

• XIP: UCLB's IP licensing portal for online licensing of software and tangible materials developed at UCL.

Products and services

• XIP IP Licensing Portal UCLB's electronic IP licensing portal enabling online licensing of software and tangible materials developed at UCL via a single accessible platform with clear licensing terms and automated approval processes for academic and commercial users.
• Spinout Development & Management

Quantifiable outcome

• 95 active spinout companies collectively raised £3.06bn in external investment
• +3 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Four partnerships are on record, tiered core, flagship and major.

• UCL (University College London)coreStrategic or Co-development PartnerUCLB is a wholly owned subsidiary of University College London, serving as the university's dedicated technology transfer and commercialization company. UCL provides the research pipeline that UCLB commercializes through spinouts and licensing.
• Quantum MotionflagshipStrategic or Co-development PartnerQuantum Motion is a spinout company from UCL and Oxford, pioneering CMOS-based quantum computing using standard silicon fabrication processes. UCLB holds interest in this spinout which delivered the industry's first full-stack silicon quantum computer to the UK National Quantum Computing Centre.
• UCL Spinout CompaniesflagshipStrategic or Co-development Partner95 active spinout companies including Unibuddy (raised £29M+), MotionInput Games, Quantum Motion (£42M Series B), and others across life sciences, deep tech, and AI sectors.
• LIGAND-AI ConsortiummajorStrategic or Co-development PartnerUCL leads a €60 million global AI-driven drug discovery initiative called LIGAND-AI involving 18 partners across nine countries, with Pfizer and the Structural Genomics Consortium as key partners.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Edinburgh Research & Innovation (ERI): University of Edinburgh's commercialization arm, providing IP licensing, spinout support, and research services. Comparable UK Russell Group TTO with life-sciences and deep-tech deal flow.
• Imperial College Innovations: Imperial College London's technology transfer function commercializing research through spinouts and licensing. Comparable London-based TTO with strong STEM/healthcare focus similar to UCLB.
• Oxford University Innovation: Oxford's dedicated technology transfer and spinout creation company. Directly comparable to UCLB as a UK Russell Group TTO commercializing world-class research through licensing, equity, and spinout formation, with overlapping deep-tech and life-sciences deal flow.
• Cambridge Enterprise: University of Cambridge's technology transfer office handling licensing, spinouts, and equity. Closely comparable to UCLB given similar research intensity, deep-tech orientation, and global brand in university innovation.
• King's College London Ventures: King's College London's commercialization function focused on health and life sciences. Comparable London-based TTO with similar healthcare IP licensing and spinout activities.
• Manchester Innovation Factory / UoM Intellectual Property: University of Manchester's technology transfer arm handling spinouts and licensing across materials, life sciences, and engineering. Comparable UK Russell Group TTO.

Others

• Parkwalk Advisors: UK fund manager specializing in university spinout and technology IP investments. Comparable ecosystem participant that co-invests alongside TTOs like UCLB in UK university spinouts.

Broad incumbents

• MIT Technology Licensing Office (TLO): MIT's technology transfer office, one of the largest and most established globally. Comparable as a leading university TTO, though at significantly greater scale and with deeper commercialization infrastructure.
• Stanford Office of Technology Licensing (OTL): Stanford's technology licensing office handling IP from one of the world's most prolific university ecosystems. Comparable TTO operating model but at much larger scale and with deeper Silicon Valley network.

Regional players

• ETH transfer (Switzerland): ETH Zurich's technology transfer office, a leading European university TTO with deep tech and quantum spinouts. Comparable function and research profile but serves Swiss/European markets rather than the UK.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/UCL_Business
• LinkedInlinkedin.com/company/ucl-business-ltd

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments41 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about UCLB